Hims & Hers jumps 40% after announcing Novo Nordisk partnership for Ozempic and Wegovy

Interesting development in the telehealth space.

Hims & Hers ($HIMS) surged roughly 40% in a single day after announcing a partnership with Novo Nordisk that will allow the company to offer Ozempic and Wegovy through its platform.

These GLP-1 drugs have quickly become some of the most in-demand pharmaceuticals globally, driven by their effectiveness for both diabetes and weight loss.

For Hims, the agreement potentially opens the door to a major new revenue stream tied to one of the fastest-growing areas in healthcare.

At the same time, the size of the market reaction highlights how quickly sentiment can shift around companies tied to the GLP-1 ecosystem.

Curious how people here see this playing out for $HIMS and telehealth platforms over the next few years.

Saw this being discussed on Blossom, which is what made me to dig into the news.

Source: [https://www.cnbc.com/2026/03/09/novo-nordisk-ends-legal-proceedings-hims-hers-compounded-weight-loss-drugs.html](https://www.cnbc.com/2026/03/09/novo-nordisk-ends-legal-proceedings-hims-hers-compounded-weight-loss-drugs.html)